TheraVet 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Gaetan Terrasse

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	n/a
경영진 평균 재임 기간	데이터 없음
이사회 평균 재임 기간	2.9yrs

최근 관리 업데이트

Recent updates

CEO

Gaetan Terrasse

no data

테뉴어

Gaetan Terrasse is Managing Director of TheraVet SA from November 15, 2024.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Simon Wheeler	Independent Director	2.9yrs	데이터 없음	데이터 없음
Nesya Goris	Independent Director	2.9yrs	데이터 없음	데이터 없음
Olivier Gauthier	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Marc Balligand	Chairman of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Guillaume Ragetly	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Ulrich Rytz	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Emmanuel Huynh	Chairman	no data	데이터 없음	데이터 없음

2.9yrs

평균 재임 기간

경험이 풍부한 이사회: ALVET 의 이사회는 경험(평균 재직 기간 2.9 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

TheraVet 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

EGEIRO Pharma Announces Management Changes

TheraVet SA, Annual General Meeting, Jun 05, 2025

TheraVet Appoints Rodolphe Lebrun as Chief Financial Officer

Less than half of directors are independent

Less than half of directors are independent

Recent updates

EGEIRO Pharma Announces Management Changes

New minor risk - Shareholder dilution

First half 2024 earnings released: €0.26 loss per share (vs €0.28 loss in 1H 2023)

New major risk - Revenue size

TheraVet SA, Annual General Meeting, Jun 05, 2025

TheraVet SA Announces Early Completion of Patient Recruitment of the Visco-VET Clinical Study

New major risk - Financial position

Third quarter 2023 earnings released

New major risk - Revenue and earnings growth

New minor risk - Financial data availability

TheraVet SA Announces the Launch of BIOCERA-VET Equine

TheraVet SA Announces Commercial Launch of Biocera-VET in Germany

TheraVet Announces Agreement with Alcyon Italia for the Distribution of BIOCERA-VET® Product Line in Italy

TheraVet SA Announces Launch of Biocera-Vet Canine Osteosarcoma Study Conducted by the University of Florida

TheraVet SA announced that it expects to receive €1 million in funding

TheraVet SA announced that it expects to receive €1 million in funding

TheraVet Appoints Rodolphe Lebrun as Chief Financial Officer

New major risk - Share price stability

TheraVet SA Announces Patient Recruitment Phase Successfully Completed in Biocera-Vet Fracture Revision Surgery Study in Toy Dogs

First half 2023 earnings released

TheraVet SA to Report First Half, 2024 Results on Sep 12, 2024

TheraVet SA Announces the Commercial Launch of A Local and Sustained Antibiotic Releasing Bone Substitute

Full year 2022 earnings released

Less than half of directors are independent

TheraVet SA to Report First Half, 2023 Results on Sep 06, 2023

First half 2022 earnings released: EPS: €0 (vs €0.24 loss in 1H 2021)

TheraVet SA to Report First Half, 2022 Results on Sep 09, 2022

TheraVet Announces the Commercial Launch of its BIOCERA-VET Product Line in the United States of America

TheraVet SA Announces the Commercial Launch of the Bone Substitutes in the Veterinary Market

Less than half of directors are independent

TheraVet SA to Report Fiscal Year 2021 Results on Apr 06, 2022

TheraVet SA Broadens Bone Substitutes Portfolio with an Innovative Line of Biological Bone Grafts

TheraVet SA presents Positive Results of Biocera-Vet-Bone Surgery Presented at the Annual Conference of the US Veterinary Orthopedic Society and Confirmed on a Larger Patients Cohort

Theravet Announces Commercial Launch of Biocera-Vet® for Canine Osteosarcoma in Belgium, France and the Netherlands

TheraVet Announces the Launch of the Pivotal European Multicentric Clinical Study of VISCO-VET in Canine Osteoarthritis

TheraVet Announces Positive Safety and Efficacy Results for VISCO-VET in Canine Osteoarthritis

TheraVet Extends the Use of BIOCERA-VET to a New Curative Approach of Osteosarcoma in Dogs Through an Innovative and Multidisciplinary Management

CEO

테뉴어

이사회 구성원

평균 재임 기간